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statin mono-therapy. Overall 55% of the patients were at target
(56% of PP and SP patients and 54% of MS patients). Multi-
variate analyses of the patient/physician questionnaire from 7
countries that contributed to the complete dataset showed that
non-adherence to LLD intake was an important determinant for
not reaching LDL-C targets (OR: 0.57; [95% CI, 0.48–0.91]).
CONCLUSION: More than 40% of European patients using
LLD are not on target for LDL-C. Measures to increase adher-
ence may have signiﬁcant impact to reach LDL-C targets.
CARDIOVASCULAR DISEASE—Methods and Concepts
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OBJECTIVES: Clinicians have a strong tendency to round blood
pressure (BP) readings, particularly to the closest multiple of ten,
even when using precise digital devices. This poses a challenge
for classifying patients as controlled in economic evaluations
when values fall on the boundary of the deﬁnition (e.g., 140/
90 mmHg), since including or excluding the boundary values will
over- or under-estimate control rates. We describe a simple
sensitivity analysis to gauge the impact of rounded readings.
METHODS: The method attempts to correct the excess number
of values ending in zero by redistributing these in the 5 mmHg
range around the observed value. Thus, a value of 140 mmHg is
replaced by a new hypothetical measurement drawn randomly
between 135–144 mmHg. The correction is made for 90% of
observations falling on the boundary since 10% would naturally
be expected to end in zero. We illustrate the method with simu-
lated data and validate by comparing the proportion below the
threshold with the true, the rounded and the corrected BPs. The
correction was applied to data from an ongoing study of a
hypertension control education program. RESULTS: A sample of
1000 random systolic BPs was generated with mean 155 and
variance 30; these “true” data were then distorted by rounding
40% of values (as observed in the study). The 30.8% in the true
data that were controlled (<140 mmHg) dropped to 28.6% after
rounding; after the correction, the proportion was 30.9%. In
time-to-control (<140/90 mmHg) analyses of the study data,
34.2% of patients had controlled BP at 6 months based on the
observed data. Replicating the analyses with corrected BPs
yielded an estimate of 41.9%. CONCLUSION: The impact of
rounding should be taken into account in analyses of BP data to
minimize bias in control rates, as well as attenuation of treatment
effect estimates that might result.
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OBJECTIVES: In real life patients are not randomly assigned to
the study groups. Thus, the results of reality may be biased by
confounders and heterogeneity. Unsuitable propensity score esti-
mators (PSEs) and explanatory techniques, which are used to
control for observed confounders, may also bias the results. The
PSEs, popular explanatory analysis techniques and the outcomes
of acute coronary heart disease (ACHD) are assessed here.
METHODS: A total of 171 Finnish ACHD patients underwent
medication, percutaneous transluminal coronary angioplasty
(PTCA) or coronary artery bypass grafting (CABG). In a pro-
spective 3-month period, demographics, coronary angiography
results, costs and 15D-based quality of life were collected.
Various multinomial methods including multinomial logistic
(MLRA), stereotype logistic and nested logistic regression analy-
sis as well as naive Bayes classiﬁer was used to elicit the best PSE
using the patients in the data. Ordinary least squares (OLS) RA
with and without ln-transformations as well as generalized linear
models (GLM) were used for the explanatory RA. Multiple mea-
sures (e.g. probability, likelihood, AIC, BIC, deviance, R2,
RMSE, RESET and link-test) ranked the techniques. ACHD out-
comes were reported using unadjusted, adjusted and PS adjusted
estimation. RESULTS: Generally, the best PSE in this study was
MLRA—one additional marker was the fulﬁllment of indepen-
dence of irrelevant alternatives (IIA). In explanatory analysis,
OLS worked well for the QALY effectiveness estimates, which
ranged -0.053–-0.031 for medication, -0.013–0.009 for PTCA,
and 0.010–0.036 for CABG depending on the use of adjustment/
PSE. The ln-transformed OLS gave the best ﬁt for cost data. The
Duan-smoothed estimates for the maximum cost difference were
4.6% for medication, 0% for PTCA, and 14.1% for CABG
depending on the use of adjustment/PSE. CONCLUSION: The
analyses of different PSEs and explanatory models offer tools to
assess the ﬁtness of the models. Observational studies should be
adjusted, favorably using PSE. Thus, the sensitivity analysis of
PSEs is important.
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OBJECTIVES: To evaluate the performance of statin medica-
tions from a retrospective set of prescription and lab data.
METHODS: A high-risk, hyperlipidemic population from a large
western US integrated health plan was screened to identify
patients with a six-month period of anti-hyperlipidemic absti-
nence prior to an initial statin, with at least one subsequent
LDL-C measurement following a minimum four- month period.
Statin treatment effect was evaluated over a sub-sample of
patients who did not switch or augment. Instead of discarding
observations, a combination selection/treatment regression
model was created. The effect of atorvastatin and typical 3rd tier
statins (atorvastatin and rosuvastatin) on change in LDL-C,
adherence, treatment goal attainment (<100 mg/dL), and titrata-
tion was evaluated using two-step and FIML estimators. Change
in LDL-C was estimated using a bivariate selection rule. For
binary dependent variables, two-step FGLS and FIML (trivariate
selection rule) were used. Concomitant diabetes, hypertension,
age, and gender were exogenous regressors in the outcome equa-
tion. For the decision equations, distance from goal at baseline
was included. Recursive and non-recursive decision equations
were utilized. RESULTS: There were 2724 continuously enrolled
patients meeting the initial inclusion criteria. Atorvastatin
(n = 1119) was associated with an increase (signiﬁcant, p < 0.05,
and insigniﬁcant, depending on the model) in LDL-C relative to
other statins (n = 1605). Atorvastatin was associated with a
higher insigniﬁcant probability of adherence and a higher signiﬁ-
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cant (p < 0.05) probability of goal attainment. Results related
to titration were equivocal. When compared to 1st and 2nd
tier statins (lovastatin, pravastatin, simvastatin, ezetimibe/
simvastatin), 3rd tier statins (n = 1171) demonstrated results
similar to atorvastatin. Condition indices were consistently <30.
Prescription data period: October 2004 to July 2006. CONCLU-
SION: Atorvastatin and 3rd tier statins were signiﬁcantly better
at achieving treatment goal in high-risk, hyperlipidemic patients.
Otherwise, atorvastatin and 3rd tier statins failed to outperform
comparators.
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OBJECTIVES: To empirically evaluate the predictive perfor-
mance and risk factor identiﬁcation of P-Course and compare it
to logistic regression (LR) using patients screened for the pres-
ence of coronary heart disease (CHD). P-Course is a web-based
naive Bayes classiﬁcation (NBC) tool which special feature is its
ability to utilize informative priors in model construction.
METHODS: 597 CHD-suspected patients underwent coronary
angiography. P-Course was compared to various forms of novel
LR approaches (full LR, backward stepwise selection using
Bayesian Information Criterion (BIC), and Bayesian Model
Averaging (BMA) with medically supported interactions). Pre-
dictive performance was measured as the proportion of cor-
rectly classiﬁed patients. The dataset was randomly split into
training and test sets. Performance was measured separately for
four different sizes of training sets (150, 200, 300, and 450).
For each size, the experiment was replicated 20 times to
improve accuracy. RESULTS: P-Course outperformed LR
approaches: the respective ranges for the average accuracies of
P-Course, full LR, stepwise BIC, and BMA with same datasets
were 0.78–0.81, 0.70–0.81, 0.70–0.80, and 0.78–0.80. In total
splits modeled (N = 3000–9000), P-Course predicted correctly
on average 63 cases more than the best comparator, BMA. The
analyses further illustrate that relevant prior information
improves P-Course’s accuracy, in particular when the training
dataset is relatively small: average accuracies with informative
and uninformative priors using training sets of sizes 25–50
were 0.70–0.71 and 0.66–0.68, respectively. In variable screen-
ing, P-Course yielded medically sensible choices of variables
regarded as the most likely risk factors for CHD. CONCLU-
SION: In addition to previous work done with P-Course (e.g.,
Naïve Bayesian Fusion and decision rationality analysis), this
analysis demonstrated the tool’s additional value in comparison
to the LR approaches. When the estimation of e.g. propensity
scores or adverse events is of concern, NBC can offer additional
predictive value compared to LR. In medicine, even one unnec-
essary faulty prediction is too much.
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OBJECTIVES: Due to joint risk factors, positive screening results
are often not only associated with mortality speciﬁc for the target
disease of screening, but also with an increased mortality due to
other causes. Most decision-analytic models do not consider this
association leading to potentially biased results. Our goal was to
develop a tool which helps to adjust for such joint mortality.
METHODS: We developed a function HR_other(HR_target)
characterizing the relationship between two mortality hazard
ratios (HRs). HR_target compares the mortality rate due to the
target disease among those at high risk versus low risk. HR_other
compares the respective mortality rates not directly related to
the target disease. We postulated several properties that must be
fulﬁlled by this function: 1) if the screening test result does not
explain the mortality (i.e. HR_other(HR_target) = 1) of the
target disease it also does not explain mortality due to other
causes; 2) the function HR_other(HR_target) is strictly increas-
ing in HR_target; 3) the relationship of HRs below 1 is derived
by taking the reciprocal values of the corresponding HRs above
1; 4) the function has an upper bound; 5) in the range of HRs
above 1, HR_target exceeds HR_other; and 6) the function
HR_other(HR_target) is continuously differentiable. We created
a function sufﬁcing all postulated properties and applied it in the
context of predictive coronary artery disease (CAD) screening.
We ﬁtted the function based of published HRs. Finally, we
applied this function to hypothetic screening methods, for which
only the HRs due to CAD were assumed to be known. The
generated HR_other can be used by decision-analysts for incor-
poration into their CAD decision-analytic models. CONCLU-
SION: We created a useful function that can be used for the
adjustment of differential non-target-disease related mortality
among risk groups in decision-analytic screening models. This
should result in more valid modeling results.
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OBJECTIVES: A comparative cost-effectiveness analysis of
generic versions of atorvastatin (atva) and simvastatin (simva)
with rosuvastatin (rosva) in patients with primary hypercholes-
terolemia in the RF. METHODS: This study compared two
brands of atva—Atoris (KRKA) and Tulip (LEK), and one of
simva—Vasilip (KRKA) with rosva—Crestor (AZ). Efﬁcacy data
in terms of percentage reduction in LDL cholesterol and propor-
tion of patients to European LDL cholesterol goals was taken
from the STELLAR trial. Price per pack data was obtained
in RUR from the wholesale Protek price-list (20.07.2006).
Exchange rate is 25.98 RUR per 1 USD and 34.75 RUR per 1
Euro. Meta-analysis of all available comparative clinical trials
has shown a relative effective dose of 1:3 for rosva compared
with atva and 1:8 for rosva vs simva. Hence cost and
efﬁcacy data for rosva 10 mg is compared with atva 30 mg
(20 mg + 10 mg) and with simva 80 mg (40 mg + 40 mg) in the
form cost per patient per year and cost per patient to European
LDL cholesterol goals. RESULTS: The cost per patient to LDL-C
goal for Crestor 10 mg is 17,914 RUR, for Atoris 30 mg, Tulip
30 mg and Vasilip 80 mg is 25,968; 25,372 and 27,692 RUR
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